-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4578 Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, Clinical Research, Diseases, Treatment Considerations, Lymphoid Malignancies, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Somedeb Ball, MD1, Surendra Neupane2*, Hannah Newman2*, Joshua A Traina2*, Najla H. Al Ali, Ms3*, Abhishek Dhawan, PhD2*, Praneeth Reddy R Sudalagunta, PhD4*, Ariosto Siqueira Silva, PhD2*, Danny DeAvila2*, Mohammad Omar Hussaini, MD5*, Jinming Song, MD, PhD6*, Zhuoer Xie, MD, MS7, Onyee Chan, MD8*, Alison R. Walker, MD, MBA, MPH9, Christopher Ryder2*, Andrew T. Kuykendall, MD3, Jeffrey E Lancet, MD3, Lubomir Sokol, MD, PhD3, Brent Ferrell Jr., MD10, Ling Zhang, MD11*, Michael R. Savona, MD10*, David Sallman, MD3, Javier Pinilla-Ibarz, MD, PhD3, Rami S. Komrokji, MD7, Kenneth H. Shain, MD, PhD2 and Eric Padron, MD12

1Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN
2H. Lee Moffitt Cancer Center, Tampa, FL
3Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
6Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
7Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
8H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Wesley Chapel, FL
10Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
11Hematopathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, FL
12Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

The incidence of synchronous dual hematologic neoplasms (SDHN) of myeloid (M) and lymphoid (L) lineage has long been recognized as higher than would be predicted based on the incidence of each respective disease alone. While the exact pathobiology remains unknown, explanations include a permissive microenvironment, synergistic selection, and/or a shared clonal origin. The latter hypothesis is supported by presence of specific pathogenic variants in both M and L HNs, with diverse, and sometimes discordant prognostic and therapeutic implications [e.g., SF3B1 in myelodysplastic syndrome (MDS) and chronic lymphocytic leukemia (CLL)]. To determine whether SDHNs share a common clonal origin, have distinct clinical outcomes, and should be considered a unique disease entity, we employed several clinical and advanced molecular approaches.

First, we identified SDHN cases with MDS and concomitant multiple myeloma (MM) or CLL and compared clinical outcomes and genetic features to cases with MDS alone. Despite no difference in MDS risk stratification by revised international prognostic scoring system, patients with SDHN (n=37) had significantly worse overall survival (24.2 vs. 39.6 months; p=0.005) than isolated MDS (n=2434). Interestingly, rate of transformation to acute myeloid leukemia (AML) was lower in SDHN group (12.9% vs. 31.8%; p=0.02). We additionally noted a significant enrichment for TP53 (46% vs. 20%; p<0.001), ASXL1 (35% vs. 21%; p=0.03), and SF3B1 (31% vs. 17%; p=0.02) mutations in SDHN-MDS compared to isolated MDS, suggesting that SDHN is characterized by distinct clinical and molecular features.

Next, we sought to determine whether SDHNs are of common clonal origin, utilizing a single-cell DNA-sequencing (scDNA-seq) and surface proteome-based multi-omic assessment on 16 cryopreserved mononuclear cell samples from 14 unique patients with SDHN. This enabled us to evaluate mutations in the above genes enriched in SDHN plus 42 other recurrently mutated genes within cellular subsets defined by immunophenotypes (IPT). These SDHNs had MDS (n=8), chronic myelomonocytic leukemia (CMML) (n=1), AML (n=3), or myelofibrosis (n=2) as their M-HN, and CLL (n=7), MM (n=6), or lymphoplasmacytic lymphoma (n=1) as their L-HN. Two SDHN cases (MDS+MM and AML+CLL) had sequential samples pre- and post-treatment. The Mosaic package was used to delineate surface protein-defined clusters that were projected in UMAP space and cell types were assigned based on manually curated IPT in a patient specific manner. Bone marrow morphology and flow cytometry data from the scDNAseq timepoint were used to corroborate the relative proportions and IPT of M and L malignant subpopulations.

Using this approach, we observed that the scDNA-seq defined dominant clone was invariably composed of M, L, and hematopoietic stem and progenitor cell (HSPC) compartments. For example, in a sample with pathologically defined CMML and MM, the dominant TET2 double-mutant clone was present in 53% of M cells, 26% of L cells, and 13% of HSPCs. In another sample of MDS and CLL, the dominant clone driven by TP53 loss of heterozygosity was distributed equitably among M (26%), L (21%), and HSPC (28%) populations. On analysis of sequential samples of a TP53-mutated SDHN (AML+CLL), the dominant clone remained present in M and L subpopulations at both pre- and post-treatment timepoints. Overall, the median dominant clone lineage composition was 40% (IQR 15%-60%) of M cells, 18% (IQR 10%-34%) of L cells, and 30% (IQR 13%-57%) of HSPCs, compared to 7% (IQR 2%-13%) of T-cells, suggesting a common clonal origin for SDHNs. Whole exome sequencing of flow cytometry-sorted M, L, and HSPC subpopulations in select SDHN samples is ongoing to validate our findings, and results will be presented at the meeting.

Finally, we explored similarities between SDHN and mixed phenotype acute leukemia (MPAL) which is defined by shared expression of M and L markers in neoplasms with ≥20% blasts. Interestingly, we observed aberrant expression of L markers on M cells and M markers on L cells in sc analysis of SDHN. Moreover, there was statistically significant correlation (r=0.75; p=0.01) between myeloblast % and degree of IPT sharing, suggesting that SDHN parallels many features of MPAL. Collectively, our findings suggest that SDHNs have distinct outcomes and are of common clonal origin. Future studies should confirm these findings and consider SDHN as a single disease entity.

Disclosures: Siqueira Silva: KARYOPHARM: Research Funding; ABBVIE: Research Funding. Chan: Abbvie: Honoraria, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Aptitude Health: Honoraria; Novartis: Honoraria; Syndax: Membership on an entity's Board of Directors or advisory committees; Jazz: Research Funding. Kuykendall: Incyte: Honoraria; Novartis: Research Funding; PharmaEssentia: Honoraria; Protagonist Therapeutics: Honoraria, Research Funding. Lancet: Tradewell Therapeutics: Consultancy, Other: Consultant/Advisory Board; Bristol Myers Squibb: Consultancy, Other: Consultant/Advisory Board; Prelude Therapeutics: Consultancy, Other: Bristol Myers Squibb. Sokol: EUSA: Research Funding; CRISPR Therapeutics: Consultancy; Kyowa Kirin, Inc: Consultancy, Research Funding. Ferrell: Novartis: Research Funding. Savona: Boehringer, Empath Biosciences: Patents & Royalties; MDSF Foundation BOD: Membership on an entity's Board of Directors or advisory committees; Astex: Other: Grants or Contracts from entity; Abbvie, BMS, CTI, Forma, Geron, GSK, Rigel, Taiho, and Treadwell: Consultancy; Karyopharm, Ryvu, Empath Biosciences: Current equity holder in publicly-traded company; Incyte: Other: Grants or Contracts from entity. Sallman: Abbvie: Consultancy; Agios: Consultancy; Axiom: Consultancy; Gilead: Consultancy; Celyad: Consultancy; Froghorn: Consultancy; Incyte: Consultancy; Intellisphere, LLC: Consultancy; Johnson & Johnson: Consultancy; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; NextTech: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AvenCell: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; BlueBird Bio: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; Intellia: Membership on an entity's Board of Directors or advisory committees; Jasper Therapeutics: Membership on an entity's Board of Directors or advisory committees; NKARTA: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Apera: Research Funding; Jazz: Research Funding. Pinilla-Ibarz: Beigene: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; Pfizer: Consultancy; Takeda: Consultancy, Speakers Bureau; Novartis: Honoraria; Secura Bio: Consultancy, Speakers Bureau; Eli Lily: Consultancy, Speakers Bureau; Sanofi: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Bristol Meyers Squibb: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Komrokji: Servio: Honoraria; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; Servio: Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Janssen: Consultancy; BMS: Research Funding; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Shain: Karyopharm: Research Funding; BMS: Consultancy, Research Funding; Adaptive Biotech: Consultancy; Karyopharm, Janssen, Adaptive Biotechnologies, GlaxoSmithKline, BMS, Sanofi, and Regeneron: Honoraria; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Amgen: Research Funding; Takeda: Consultancy; Sanofi: Consultancy; Glaxo Smith Kline: Consultancy, Membership on an entity's Board of Directors or advisory committees.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH